Skip to main
LNTH

Lantheus Holdings (LNTH) Stock Forecast & Price Target

Lantheus Holdings (LNTH) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 17%
Buy 33%
Hold 50%
Sell 0%
Strong Sell 0%

Bulls say

Lantheus Holdings is a promising company, with a diverse product portfolio that caters to the diagnosis and treatment of various diseases, including cancer. Their recent acquisition of LNTH-2501 and the FDA's positive signal on its safety and efficacy bodes well for potential future approval and revenue generation. Additionally, their royalty opportunities, partnerships, and a solid 2027 forecast make the stock undervalued compared to its peers. The management team's efforts to find a permanent CEO and a focused approach to rolling out its new product, PYL TruVu, set the stage for potential growth.

Bears say

Lantheus Holdings is facing challenges in maintaining market share and profitability due to a dynamic reimbursement landscape and increased competition in the radiopharmaceutical industry. Their recent earnings call highlighted the need to de-risk their 2026 forecast with a conservative outlook and potential risks such as pricing pressures and delays in securing FDA approvals for new products. The company's recent leadership changes and CEO transition may also lead to operational and execution challenges. These factors contribute to a negative outlook for the company's stock.

Lantheus Holdings (LNTH) has been analyzed by 6 analysts, with a consensus rating of Buy. 17% of analysts recommend a Strong Buy, 33% recommend Buy, 50% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Lantheus Holdings and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Lantheus Holdings (LNTH) Forecast

Analysts have given Lantheus Holdings (LNTH) a Buy based on their latest research and market trends.

According to 6 analysts, Lantheus Holdings (LNTH) has a Buy consensus rating as of Aug 30, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $106.83, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $106.83, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Lantheus Holdings (LNTH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.